Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Ltd ( (HK:9688) ) just unveiled an update.
Zai Lab Limited has announced a change in its head office and principal place of business in the People’s Republic of China. Effective July 1, 2025, the company’s new location will be in Pudong, Shanghai. This move may indicate strategic positioning within the region, potentially impacting its operational efficiency and market presence in China.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative medicines. The company operates primarily in the healthcare sector, with a market focus on addressing unmet medical needs in China and globally.
YTD Price Performance: 32.06%
Average Trading Volume: 12,569,354
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.6B
Learn more about 9688 stock on TipRanks’ Stock Analysis page.